WHEN IS CATARACT SURGERY NOT ENOUGH TO MANAGE GLAUCOMA?

For patients with uncontrolled IOP, a combination procedure may be more appropriate.

BY NIR SHOHAM-HAZON, MD

In Western Europe, an estimated 3.2 million cataract surgeries are performed each year. Among individuals diagnosed with cataracts, around 9% have a coexisting diagnosis of glaucoma. With these numbers only increasing as the population ages, cataract surgeons are frequently faced with patients presenting with concomitant cataract and glaucoma.

Many surgeons view cataract surgery itself as a glaucoma procedure because it has IOP-lowering effects. A number of studies have shown that phacoemulsification can lower IOP, and strong evidence indicates that phacoemulsification is a better and safer treatment than either peripheral iridotomy or phacotrabeculectomy. For patients with concomitant cataract and glaucoma, the reduction in IOP seen after cataract surgery is an added benefit that may offer better postoperative IOP control than these other procedures.

Should IOP reduction after cataract surgery be insufficient, topical therapy may be augmented or initiated, and laser trabeculoplasty or frank filtration surgery may be warranted. With that said, cataract surgery can result in an increase in IOP postoperatively in some patients. It is, therefore, vital to choose appropriate patients for standalone and combined procedures. In this article and in the accompanying graphic, I outline how and when I select cataract surgery alone or in combination with other procedures to control IOP in glaucoma patients.

WHEN IS CATARACT SURGERY ALONE SUFFICIENT?

Cataract surgery can be effective in lowering IOP, particularly in patients with angle-closure glaucoma (ACG). A recent review of the literature by the AAO assessed the effect of cataract surgery on IOP. The authors found that patients with ACG experienced a 30% reduction in IOP and a 58% reduction in the number of glaucoma medications needed after phacoemulsification. Patients with other forms of glaucoma who have little or no optic disc damage or visual field defects, and whose IOP is adequately controlled on medications, can also do well with standalone cataract surgery.

WHEN TO COMBINE WITH OTHER PROCEDURES

When it comes time for cataract surgery, some glaucoma patients need more than phacoemulsification alone to help reduce IOP in open-angle glaucoma (OAG) patients is more controversial. The same AAO report found that patients with OAG experienced significantly smaller benefits than those seen in patients with ACG, with only a 13% reduction of IOP and 12% reduction in number of medications. Two randomized controlled trials did demonstrate significant IOP reductions after cataract surgery; however, both had methodologic issues, including small sample sizes and the inclusion of no untreated control groups and no true glaucoma patients.

Conversely, a prospective study of 63 patients in Japan demonstrated that patients with OAG undergoing phacoemulsification tended to have an increase in IOP postoperatively. In that trial, 13% of OAG patients had IOP spikes to greater than 30 mm Hg postoperatively, whereas no patients in a control group experienced spikes. However, as higher preoperative IOP appears to be proportional with higher postoperative IOP, preoperative IOP levels may be used as a predictor for postoperative outcomes.

However, the efficacy of using phacoemulsification to reduce IOP in open-angle glaucoma (OAG) patients is more controversial. The same AAO report found that patients with OAG experienced significantly smaller benefits than those seen in patients with ACG, with only a 13% reduction of IOP and 12% reduction in number of medications. Two randomized controlled trials did demonstrate significant IOP reductions after cataract surgery; however, both had methodologic issues, including small sample sizes and the inclusion of no untreated control groups and no true glaucoma patients.

Conversely, a prospective study of 63 patients in Japan demonstrated that patients with OAG undergoing phacoemulsification tended to have an increase in IOP postoperatively. In that trial, 13% of OAG patients had IOP spikes to greater than 30 mm Hg postoperatively, whereas no patients in a control group experienced spikes. However, as higher preoperative IOP appears to be proportional with higher postoperative IOP, preoperative IOP levels may be used as a predictor for postoperative outcomes.

AT A GLANCE

- Many surgeons view cataract surgery itself as a glaucoma procedure because it has IOP-lowering effects.
- Factors such as the number of medications a patient with glaucoma is taking, the stage of his or her disease, and the current and target IOPs should be considered when determining whether to combine cataract surgery with another procedure to lower IOP.
- With a phaco-plus procedure, the surgeon must consider whether to use a MIGS approach or a more invasive glaucoma surgical procedure.
control the chronic disease. These include patients with moderate or advanced glaucoma who have uncontrolled IOP despite using several medications and having undergone previous trabecuoplasty. These patients likely have an outflow facility compromise either in or distal to the trabecular meshwork.

Such patients may benefit from a phaco-plus procedure. Phaco-plus is a term describing a combined procedure: either cataract surgery plus microinvasive invasive glaucoma surgery (MIGS) or cataract surgery plus penetrating filtration surgery. Patients with significant disc and visual field damage and with borderline or uncontrolled IOP may benefit from a combined procedure.

If a patient’s IOP is borderline or above target pressure and the patient has mild to moderate glaucoma with mild to moderate visual field defects, that patient needs to achieve a postoperative IOP in the mid-teen range and would benefit from phacoemulsification plus MIGS. MIGS procedures include iStent implantation (Glaukos), trabeculotomy with the Trabectome (NeoMedix), endocyclophotocoagulation, implantation of a Xen gel stent (Allergan), ab interno canaloplasty performed with the iTrack illuminated microcatheter (Ellex), or goniotomy with the Kahook Dual Blade (New World Medical).

As the risk associated with MIGS is low and many MIGS procedures were conceived to be performed in combination with cataract surgery, I typically offer this phaco-plus option for patients who have mild to moderate glaucoma. This generally reduces IOP to the middle to lower teens and often eliminates or reduced the number of medications needed, even for patients with unstable pressures, without adding risk to the procedure.

Patients with moderate to advanced glaucoma despite two or more medications need to achieve a target IOP in the lower teens, which requires phacoemulsification plus a more involved procedure such as trabeculectomy or CO₂ laser-assisted sclerectomy surgery (CLASS) with the IOPtiMate CO₂ laser system (IOPtima). The nonpenetrating CLASS procedure has been shown to be safer and more effective than other nonpenetrating glaucoma procedures. It provides IOP control similar to that of trabeculectomy,¹²-¹⁴ and it can be performed by cataract and glaucoma surgeons as a standalone procedure or in combination with phacoemulsification. CLASS is appropriate for use in patients with primary OAG and pseudoexfoliative glaucoma.

In CLASS, similar to trabeculectomy, the surgeon performs a peritomy and creates a small scleral flap. The Schlemm canal is then essentially unroofed as the laser thins the scleral wall above the canal, which allows aqueous percolation to reduce IOP. The CO₂ laser energy is absorbed by the percolating aqueous humor, preventing its penetration into the eye. This self-regulating safety mechanism, along with the absence of shunts, tubes, and other foreign bodies, reduces the risk of complications compared with other procedures.

If the patient’s target IOP range has not been reached by 6 weeks after the CLASS procedure, the surgeon can perform another simple procedure such as Nd:YAG laser goniopuncture in order to try to reach the target IOP.

CONCLUSION

In any patient with coexisting glaucoma and cataract, factors such as the number of medications the patient is taking, the stage of the
WHY CATARACT SURGERY SHOULD BE AN INFLECTION POINT IN GLAUCOMA MANAGEMENT

By Kuldev Singh, MD, MPH

The world of glaucoma care is rapidly changing, with an explosion of new technologies for microinvasive glaucoma surgery (MIGS). But even before these tiny devices, usually implanted at the time of cataract surgery, began to appear, there was a growing realization among ophthalmologists that cataract surgery itself was a glaucoma procedure.

For at least the past decade, it has been recognized that cataract surgery, on average, lowers IOP in both normotensive and hypertensive eyes. The IOP-lowering effect of cataract removal and IOL implantation is proportional to the patient’s preoperative IOP; that is, the decrease is greatest in patients with the highest IOPs before surgery. In patients with notably elevated preoperative IOP (23 to 31 mm Hg), reductions of a mean 6.5 mm Hg (27%) have been reported, whereas in those with average or low IOP the effect is more modest; in the range of 1 to 2 mm Hg. This effect has been seen to last up to 10 years.

When any MIGS procedure is done in conjunction with cataract surgery, therefore, the patient, on average, may get the bonus of extra IOP lowering from lens removal. There are other benefits of having the lens out sooner rather than later in glaucomatous eyes. For example, in the event that a patient’s glaucoma progresses and a trabeculectomy is needed, it is better to have previously removed the lens rather than risking trabeculectomy failure related to cataract surgery following successful trabeculectomy.

For these and other reasons, I believe that cataract surgery makes subsequent glaucoma management easier. As safe as some MIGS procedures appear to be from published reports, ophthalmologists need to start thinking about performing these surgical glaucoma interventions earlier in the course of the disease rather than later. We have been used to waiting to perform surgery because of the risks involved with penetrating procedures such as trabeculectomy and tube shunt implantation. Now, some MIGS procedures combined with cataract surgery appear to have safety profiles similar to that seen with cataract surgery alone.

LIVING LONGER WITH GLAUCOMA AFTER CATARACT SURGERY

Another factor in this equation is the aging of the population. Patients are increasingly living into their 90s and beyond, so we are going to have many more older patients with glaucoma who will need our care. With patients living longer and having cataract surgery earlier, the number of post–cataract surgery years will be greater for the average glaucoma patient in the future. Thus the impact of a successful glaucoma surgical procedure performed at the time of cataract surgery can include reduced medication dependence and improved glaucoma care for longer than in prior generations. Assuming that the therapies work, this is clearly a good approach from a public health perspective.

CONCLUSION

The average period of post–cataract surgery glaucoma care, which in the past might have been 5 to 10 years, is likely to be 20 or more years for future generations of glaucoma patients. If we can make cataract surgery an inflection point—a MIGS procedure that will help to decrease the patient’s IOP and/or medication dependence for a period of many years after cataract surgery—we will undoubtedly improve glaucoma care.

Kuldev Singh, MD, MPH

- Professor of Ophthalmology, Stanford University, Palo Alto, California
- Kuldev.singh@stanford.edu
- Financial disclosure: Consultant (Alcon, Allergan, Ivantis, Glaukos, Santen)


Nir Shoham-Hazon, MD

- Director of Glaucoma, Cataract, and Advanced Anterior Segment and IOL Surgery, Department of Ophthalmology, Barzilai University Medical Center, Ashkelon, Israel
- nir.eye@rne.com
- Financial disclosure: Consultant (IOPTima, Allergan, Neomedix)